12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trelstar triptorelin pamoate regulatory update

FDA accepted for review an NDA from Watson for a 6-month formulation of 22.5 mg Trelstar triptorelin pamoate for palliative treatment of...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >